Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors.

Dwight E. Yin  
*Children's Mercy Hospital*

Christina Ludema  
Stephen R. Cole  
Carol E. Golin  
William C. Miller

*See next page for additional authors*

Follow this and additional works at: [https://scholarlyexchange.childrensmercy.org/papers](https://scholarlyexchange.childrensmercy.org/papers)

**Recommended Citation**

Yin, D. E., Ludema, C., Cole, S. R., Golin, C. E., Miller, W. C., Warshaw, M. G., McKinney, R. E., . Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors. *PLoS One* 15, 0242405-0242405 (2020).
RESEARCH ARTICLE

Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors

Dwight E. Yin, Christina Ludema, Stephen R. Cole, Carol E. Golin, William C. Miller, Meredith G. Warshaw, Ross E. McKinney, Jr, on behalf of the PENPACT-1 (PENTA 9 / PACTG 390) Study Team

Abstract

Background
Choice of initial antiretroviral therapy regimen may help children with HIV maintain optimal, continuous therapy. We assessed treatment-naïve children for differences in time to treatment disruption across randomly-assigned protease inhibitor versus non-nucleoside reverse transcriptase inhibitor-based initial antiretroviral therapy.

Methods
We performed a secondary analysis of a multicenter phase 2/3, randomized, open-label trial in Europe, North and South America from 2002 to 2009. Children aged 31 days to <18 years, who were living with HIV-1 and treatment-naïve, were randomized to antiretroviral therapy with two nucleoside reverse transcriptase inhibitors plus a protease inhibitor or non-nucleoside reverse transcriptase inhibitor. Time to first documented treatment disruption to any component of antiretroviral therapy, derived from treatment records and adherence questionnaires, was analyzed using Kaplan-Meier estimators and Cox proportional hazards models.
rather than the authors. Per IMPAACT policy, the
data cannot be made publicly available due the
ethical restrictions in the study’s informed consent
documents and in the International Maternal
Pediatric Adolescent AIDS Clinical Trials
(IMPAACT) Network’s approved human subjects
protection plan; public availability may compromise participant confidentiality. However, data are
available to all interested researchers upon request
to the IMPAACT Statistical and Data Management
Center’s data access committee (email address:
sdac.data@fstrl.org) with the agreement of the
IMPAACT Network.

Funding: DEY’s work was supported by the Eunice
Kennedy Shriver National Institute of Child Health
and Human Development (NICHD) training grants
to the Department of Pediatrics, Duke University
Medical Center (T32 HD043029) and the Division
of Infectious Diseases, Department of Pediatrics,
Duke University Medical Center (T32 HD060558).
The PENPACT-1 trial was sponsored jointly by the
Paediatric European Network for Treatment of
AIDS (PENTA) Foundation, Agence Nationale de
Recherche sur le Sida et les hepatitis virales
(ANRS) and the Pediatric AIDS Clinical Trials Group
(PACTG), subsequently named the International
Maternal Pediatric Adolescent AIDS Clinical Trials
Group (IMPAACT). Overall support for PACTG/
IMPAACT was provided by the National Institute of
Allergy and Infectious Diseases (NIAID) [U10
AI068632], the Eunice Kennedy Shriver National
Institute of Child Health and Human Development
(NICHD), and the National Institute of Mental
Health (NIMH) [AI068632]. The content is solely
the responsibility of the authors and does not
necessarily represent the official views of the NIH.
This work was supported by the Statistical and
Data Analysis Center at Harvard School of Public
Health, under the National Institute of Allergy and
Infectious Diseases cooperative agreement #5 U01
AI41110 with the PACTG and #1 U01 AI068616
with the IMPAACT Group. Support of the sites was
provided by the National Institute of Allergy and
Infectious Diseases (NIAID) and the NICHD
International and Domestic Pediatric and Maternal
HIV Clinical Trials Network funded by NICHD
(contract number N01-DK-9-001/
HHSN267200800001C). PENTA is a coordinated
action of the European Commission/European
Union, supported by the seventh framework
programme (FP7/2007-2013) under the Eurocoord
grant agreement number 260694, the sixth
framework contract number LSHP-CT-2006-
018865, the fifth framework programme contract
number QLK2-CT-2000-00150, and by the PENTA
Foundation. UK clinical sites were supported by a
grant from the MRC; those in Italy by a grant from

Results
The modified intention-to-treat analysis included 263 participants. Seventy-two percent (n = 190) of participants experienced at least one treatment disruption during study. At 4 years, treatment disruption probabilities were 70% (protease inhibitor) vs. 63% (non-nucleoside reverse transcriptase inhibitor). The unadjusted hazard ratio (HR) for treatment disruptions comparing protease inhibitor vs. non-nucleoside reverse transcriptase inhibitor-based regimens was 1.19, 95% confidence interval [CI] 0.88–1.61 (adjusted HR 1.24, 95% CI 0.91–1.68). By study end, treatment disruption probabilities converged (protease inhibitor 81%, non-nucleoside reverse transcriptase inhibitor 84%) with unadjusted HR 1.11, 95% CI 0.84–1.48 (adjusted HR 1.13, 95% CI 0.84–1.50). Reported reasons for treatment disruptions suggested that participants on protease inhibitors experienced greater tolerability problems.

Conclusions
Children had similar time to treatment disruption for initial protease inhibitor and non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy, despite greater reported tolerability problems with protease inhibitor regimens. Initial pediatric antiretroviral therapy with either a protease inhibitor or non-nucleoside reverse transcriptase inhibitor may be acceptable for maintaining optimal, continuous therapy.

Introduction
Globally, 1.8 million children are living with HIV, and 110,000 die annually due to AIDS-related illnesses [1]. For HIV-infected children, greatest survival outcomes can be achieved only with optimal, uninterrupted treatment on effective antiretroviral therapy (ART). Treatment disruptions, defined as any interruption or alteration of initial ART, may result from patient-level factors (e.g., poor adherence, drug intolerance), provider-level factors (e.g., prescription stops, changes, or errors), or systems-level factors (e.g., stock outs, interruptions in drug delivery). Unfortunately, treatment disruptions may result in treatment failure, acquisition of resistance mutations, and loss of future treatment options— which are particularly consequential in children. Compared with adults, children have greater pharmacokinetic variability and fewer available licensed drugs [2, 3]. Due to longer lifetime antiretroviral exposure, children have more potential for long-term toxicity [4, 5]. Children have greater social vulnerability related to their dependence on others for medical care and medication administration [6, 7]. If inadequately treated, children progress much faster to AIDS and death [8–10]. As children’s initial ART regimens are often their best opportunity for effective, tolerable treatment, optimizing the time on a successful initial regimen may result in greater long-term effectiveness of ART and more lifetime treatment options [11]. Analyzing longitudinal relationships between pediatric ART regimens and time to treatment disruption allows identification of initial ART regimens that pose greater challenges to maintaining optimal, continuous ART.

When deciding which regimen to prescribe to optimize clinical outcomes, clinicians must consider both drug pharmacology and potential adherence to ART regimens [12]. Boosted protease-inhibitor (PI)-based regimens appear more forgiving of treatment disruptions than do non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens [13–17]. However, certain PI characteristics decrease adherence and tolerability, particularly in children:

Time to treatment disruption in children on PIs vs NNRTIs
the Istituto Superiore di Sanita—Progetto Terapia Antivirale 2004, 2005. GSK and BMS provided drugs in Romania. The trial was coordinated by four trials centers: the Medical Research Council (MRC) Clinical Trials Unit, London, UK (with support from the MRC); INSERM SC10, Paris, France (supported by ANRS); Frontier Science, New York, USA; and Westat, Maryland, USA (supported by NICHD). CEG’s salary was partially supported by NICHD K24HD069204. Although the parent trial was overseen by members of the NIH and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision and PENA
visits. Four years of follow-up was defined as the week 192 visit plus a 6-week lag to capture late visits.

**Outcomes**

We defined time to treatment disruption as the number of weeks between randomization and the first documented treatment disruption event. We defined treatment disruption as stopping, switching, or reporting missed doses of any component of the initial ART regimen for any reason except recall of nelfinavir (June 2007) or planned treatment interruptions. Stopping was defined as any duration of treatment discontinuation, regardless of whether treatment was restarted or changed in the future, whereas switches were defined as immediate changes of therapy. Information on ART stoppages or switches was derived from participants’ treatment records, and missed doses were defined as any questionnaire-reported missed doses within 3 days prior to the study visit.

Additional analyses included adjustment for stratified randomization factors (age, receipt of perinatal ART prophylaxis, research network), assessed differences in outcome for the primary follow-up time point (4 years) vs. the entire study, and explored reasons for treatment disruptions. Reasons for treatment disruptions were analyzed using (1) the treatment record’s documented rationale for ART stop or change and (2) any questionnaire-reported barriers to adherence within 2 weeks prior to the visit when missed dose(s) were reported. Only one reason for treatment disruption was allowed on the treatment record; thus a single response, such as “caregiver request,” may not exclude additional reasons. Multiple reasons were allowed on adherence questionnaires.

We assessed the sensitivity of our results to our definition of treatment disruption. Our alternative outcome definitions included restricting treatment record-based treatment disruptions (or any questionnaire event) to drug changes or stops lasting more than 3 days or 14 days and restricting treatment record-based treatment disruptions (or any questionnaire event) to only events including the PI or NNRTI drug component.

**Statistical analysis**

PI vs. NNRTI treatment groups were assessed according to a modified intention-to-treat (mITT) analysis consistent with the original study [23]. The sole modification was removal of three participants: two who withdrew consent prior to ART initiation, and one with a major eligibility violation. Follow-up began at date of randomization. Participants were right-censored for initial treatment contrary to randomization, planned treatment interruption, death, withdrawal of consent, loss to follow-up, or study end.

For the primary outcome, we estimated the risk of treatment disruptions using the complement of the Kaplan-Meier estimator. We estimated the hazard ratio for treatment disruptions using Cox proportional hazards models. Proportional hazards assumptions were assessed graphically, using time-interaction terms, and with martingale residuals. In adjusted analyses, we stratified by baseline randomized stratification variables: age, exposure to perinatal ART, and research network. Analyses were conducted in SAS® version 9.4 (Cary, NC).

**Results**

PENPACT-1 enrolled 266 HIV-1 infected children from 68 centers in 13 countries in Europe, North America, and South America. The mITT analysis was restricted to 263 participants who initiated ART. Participants were a median age of 6.5 years at enrollment (IQR [interquartile range], 1.8–12.9), 52% male, 49% black, and 79% exposed to HIV via vertical transmission (Table 1). Fifty-one percent had moderate to severe clinical symptoms (CDC stage B or C).
Median growth parameters were below average (weight-for-age Z score -0.6; height-for-age Z score -0.9). Median CD4 Z-score was -3.5, consistent with predominance of moderate to severe immunosuppression, and median viral load was 5.0 $\log_{10}$ copies/mL. Whereas 15% of children had ART exposure for prevention of mother-to-child transmission, 4% had at least one major resistance mutation at baseline. Although treatment groups had differences in racial distribution, baseline characteristics relating to mode of HIV-1 acquisition, clinical and immunological status, and ART resistance were generally balanced across ART regimens, consistent with the randomized design.

Median follow-up time was 261 weeks (IQR, 217–313). Two participants in each arm were started on a PI or NNRTI contrary to randomization; two underwent planned treatment interruption; five withdrew from study after ART initiation; 37 were lost to follow-up; and one patient died, due to HIV-related complications (Fig 1). Two hundred forty-nine participants ever completed an adherence questionnaire, totaling 2,112 questionnaires over the duration of the study for a mean of 8.5 questionnaires per participant.

Overall, 191 of 263 participants had at least one treatment disruption event during the study, with 66% (95% confidence interval [CI] 61–72%) treatment disruption probability at 4 years (primary follow-up period) and 83% (95% CI 76–91%) treatment disruption probability at study end (6.5 years). At 4 years, probabilities of treatment disruption were 70% (95% CI 62–78%) vs. 63% (95% CI 55–72%) in the PI and NNRTI arms, respectively (Fig 2). Hazards for treatment disruption, however, were similar for PI vs. NNRTI-based regimens (unadjusted hazard ratio [HR] 1.19, 95% CI 0.88–1.61), even after adjustment for stratification factors of age, receipt of perinatal ART, and research network/region (adjusted HR 1.24, 95% CI 0.91–1.68).

After 4 years, treatment disruption probabilities converged, such that treatment disruption probabilities at study end were 81% (95% CI 72–90%) for PI vs. 84% (95% CI 73–94%) for NNRTI arms, but changes over time in the hazard ratio of treatment disruption by treatment arms were non-significant (unadjusted $P$ for interaction = 0.33, adjusted $P = 0.21$). Hazards for treatment disruption over the entire study period were similar for PI vs. NNRTI-based regimens, unadjusted (HR 1.11, 95% CI 0.84–1.48) and adjusted (HR 1.13, 95% CI 0.84–1.50).

Of 191 treatment disruption events, 126 events were based on ART regimen stoppages or changes in the treatment record, and 67 events were reported missing doses on adherence questionnaires, with two participants experiencing both event types simultaneously. Of the treatment stops or changes, 25% of events were substitutions of at least one first-line ART drug (PI 32%, NNRTI 16%), 53% were stoppage or suspension of the entire first-line ART regimen (PI 48%, NNRTI 59%), and 22% were switches to a second-line ART regimen (PI 20%, NNRTI 25%). Most frequent reasons documented for ART stops or changes were adverse events (34%), viral failure (22%), caregiver request (18%), non-adherence (7%), and temporary break (6%), with the greatest difference between PIs over NNRTIs for adverse events (Table 2).

Reports of missed doses on adherence questionnaires were balanced between PI and NNRTI arms, as 35% of non-adherence events in each arm were from patient or caregiver reports. The most common questionnaire-reported barriers to adherence, forgetting/lacking support (30%) or running out of medications (25%), were balanced between PI and NNRTI regimens. Other common questionnaire-reported adherence problems—including difficulties with administration, such as those attributed to intolerance, taste, patient refusal (24%); fear of disclosure to others (22%); patient refusal (21%); difficulties with scheduling or lifestyle (18%); and concerns about drug toxicity (16%)—were more frequently reported in participants in the PI arm (Table 2).

In sensitivity analyses, modifications of the outcome definition did not result in substantial hazard ratio changes. Point estimates at 4 years remained similar to the primary analysis when
Table 1. Baseline characteristics of study participants according to initial ART regimen.

| Variable                  | Randomized Group |       |       |
|---------------------------|-------------------|-------|-------|
|                           | PI                | NNRTI | Total |
| N                         | 131               | 132   | 263   |
| Age                       |                   |       |       |
| <3 years                  | n (%)             | 34 (26%) | 36 (27%) | 70 (27%) |
| 3–17 years                | n (%)             | 97 (74%) | 96 (73%) | 193 (73%) |
| Age in years              | Median (IQR)      | 7.1 (2.8, 13.7) | 6.4 (2.7, 11.0) | 6.5 (2.8, 12.9) |
| Sex                       |                   |       |       |
| Male                      | n (%)             | 69 (53%) | 67 (51%) | 136 (52%) |
| Race                      |                   |       |       |
| Black, Non-Hispanic       | n (%)             | 60 (46%) | 69 (52%) | 129 (49%) |
| White, Non-Hispanic       | n (%)             | 40 (31%) | 29 (22%) | 69 (26%) |
| Hispanic/Other            | n (%)             | 31 (24%) | 34 (26%) | 65 (25%) |
| Research Networka         |                   |       |       |
| PENTA                     | n (%)             | 95 (73%) | 93 (70%) | 188 (71%) |
| PACTG/IMPAACT              | n (%)             | 36 (27%) | 39 (30%) | 75 (29%) |
| Route of Infection        |                   |       |       |
| Vertical                  | n (%)             | 103 (79%) | 106 (80%) | 209 (79%) |
| Other/Unknown             | n (%)             | 28 (21%) | 26 (20%) | 54 (21%) |
| CDC Clinical Stage        |                   |       |       |
| N                         | n (%)             | 27 (21%) | 29 (22%) | 56 (21%) |
| A                         | n (%)             | 35 (27%) | 37 (28%) | 72 (27%) |
| B                         | n (%)             | 41 (31%) | 43 (33%) | 84 (32%) |
| C                         | n (%)             | 28 (21%) | 23 (17%) | 51 (19%) |
| Weight-for-Age Z-score    | Median (IQR)      | -0.5 (-1.6, 0.1) | -0.7 (-1.6, 0.2) | -0.6 (-1.6, 0.1) |
| Height-for-Age Z-score    | Median (IQR)      | -0.9 (-1.5, -0.2) | -0.9 (-1.8, 0) | -0.9 (-1.7, -0.2) |
| CD4 Z score               | Median (IQR)      | -3.6 (-7.2, -1.7) | -3.4 (-6.5, -1.4) | -3.5 (-6.8, -1.6) |
| Viral Load log_{10} copies/mL | Median (IQR) | 5.1 (4.5, 5.7) | 5.0 (4.5, 5.6) | 5.0 (4.5, 5.7) |
| Perinatal ART Exposure    | n (%)             | 19 (15%) | 20 (15%) | 39 (15%) |
| ≥1 Major Resistance Mutationb | n/N (%) | 5/116 (4%) | 5/123 (4%) | 10/239 (4%) |
| HIV-1 subtype             |                   |       |       |
| B                         | n (%)             | 52 (42%) | 49 (39%) | 101 (41%) |
| C                         | n (%)             | 13 (11%) | 12 (10%) | 25 (10%) |
| F                         | n (%)             | 25 (20%) | 23 (18%) | 48 (19%) |
| A/CRF_AG/D/G              | n (%)             | 21 (17%) | 31 (25%) | 52 (21%) |
| Unclassified              | n (%)             | 12 (10%) | 11 (9%) | 23 (9%) |
| Switching Threshold       |                   |       |       |
| 1,000 copies/mL           | n (%)             | 66 (50%) | 68 (52%) | 134 (51%) |
| 30,000 copies/mL          | n (%)             | 65 (50%) | 64 (48%) | 129 (49%) |
| Duration of Follow-Up in weeks | Median (IQR) | 263 (217, 313) | 260 (219, 316) | 261 (217, 313) |

ART, antiretroviral therapy; IQR, interquartile range; N, total sample size; n, subsample size; NNRTI, non-nucleoside reverse transcriptase inhibitor; PACTG, Pediatric AIDS Clinical Trials Group; PENTA, Paediatric European Network for Treatment of AIDS; PI, protease inhibitor.

a PENTA sites were predominantly in Europe, South America, and the Bahamas. PACTG sites were based primarily in the United States.

b Not all patients had successful baseline genotypic resistance assays.

https://doi.org/10.1371/journal.pone.0242405.t001

restricting events on the treatment record (or any event on questionnaire) to only ART regimen stops or changes lasting >3 days (unadjusted HR 1.16, 95% CI 0.85–1.57; adjusted HR 1.19, 95% CI 0.88–1.63), only ART regimen stops or changes lasting >14 days (unadjusted HR
1.27, 95% CI 0.93–1.74; adjusted HR 1.32, 95% CI 0.96–1.81), or only stops or changes including the PI or NNRTI drug (unadjusted HR 1.14, 95% CI 0.84–1.55; adjusted HR 1.18, 95% CI 0.87–1.61).

Discussion

In PENPACT-1, our estimates were not compatible with large differences in time to treatment disruption between participants randomized to PIs versus NNRTIs. Point estimates were mildly in the direction of more treatment disruptions in PI-based regimens, particularly in the primary end point of 4 years, but differences were small, possibly due to chance, and appeared to decrease by study end. Exploration of reasons for treatment disruptions suggested that PI-based regimens may be less tolerable, both due to adverse events leading to treatment stoppages or substitutions and to regimen-specific adherence barriers reported on the adherence questionnaire. However, these PI-associated difficulties did not interrupt continuous therapy to the initial PI-based regimens more than they did to NNRTI-based regimens.

Although we did not find a meaningful difference in treatment disruptions in PI vs. NNRTI-based regimens, the secondary analyses exploring reasons for treatment disruptions suggested that administration of a PI-based regimen to a child may be a struggle, even if not resulting in actual missed doses. The treatment record suggested that participants experienced more adverse events to PIs over NNRTIs, but adherence questionnaire responses formed a pattern of difficulties with PI tolerability, whether attributed to taste, medication volume or pill burden, toxicity, or simply patient refusal. This pattern would be consistent with existing literature on PI vs. NNRTI regimens. PIs have higher drug toxicity, especially gastrointestinal side effects, and intolerance, particularly regarding their noxious taste [7, 18–20, 25–27]. Even if children are able to swallow pills, certain PIs are available only as large pills [28, 29]. At the time of PENPACT-1, no PIs were available as complete-regimen combinations for children, whereas single-tablet NNRTI regimens could facilitate adherence through administration of fewer pills [2, 30–34]. More recently, a novel four-in-one fixed-dose combination of abacavir, lamivudine, and LPV/r granule-filled capsules has been under study and submitted to the...
FDA for approval [35]. Participants reported more barriers to adherence in PIs related to scheduling or lifestyle interference, which may relate to dosing frequency. We hypothesize that increased fear of disclosure to others, as noted in the PI arm, may relate to difficulties concealing drug administration when given more frequently. Higher dosing frequency has been associated with more frequent treatment disruptions [20, 30, 33, 34, 36–39]. Some NNRTIs, most notably efavirenz, have more suitable pharmacokinetics for once daily administration. In our study, most PI-based regimens were administered at least twice daily, whereas some commonly used NNRTI-based regimens allowed once-daily dosing.

Most children in PENPACT-1 experienced a treatment disruption event during the study. Only about one-third of participants remained continuously on their initial ART at 4 years; only one-sixth remained continuously on initial ART at study end. These results are consistent with other pediatric data on the durability of first-line treatment regimens [40]. Maintaining continuous therapy on ART is critical to sustained HIV-related outcomes, as suppressing viral load decreases the probability of HIV sub-populations acquiring antiretroviral resistance mutations and chances of forward infection [41–49]. Although optimal adherence targets vary by PI vs. NNRTI class, adherence has been modest across ART studies, especially patients failing to achieve viral suppression [12, 16, 17, 30, 50–56]. Notably, ART appears to be less successful in producing viral suppression in children, who are more prone to viral failure and
resistance due to higher plasma viral loads, less robust antiviral immune responses, greater pharmacokinetic variability, and social dependency [44, 57]. Adolescents have particularly worse viral and immunological outcomes, due to poor ART adherence [48, 49, 58–60]. The large proportion of children in PENPACT-1 with disruptions of their initial ART raises concerns regarding long-term durability, especially as these patients were receiving adherence support on a clinical trial protocol at specialty pediatric HIV centers.

Based on our data, choice of an initial PI- vs. NNRTI-based regimen may not have a major impact on ART treatment disruption. Despite differences in reported regimen-related adherence barriers, participants in both treatment arms persevered in taking their regimens similarly. Moreover, the most common questionnaire-reported barriers were not regimen-specific:

Table 2. Reasons listed for treatment disruption events.

| Reason / Barrier                                               | PI  | NNRTI | Total |
|---------------------------------------------------------------|-----|-------|-------|
| Treatment Record<sup>a</sup>                                  |     |       |       |
| Adverse event                                                 | 24 (37%) | 19 (31%) | 43 (34%) |
| Viral failure                                                 | 13 (20%) | 15 (25%) | 28 (22%) |
| Caregiver request                                             | 11 (17%) | 12 (20%) | 23 (18%) |
| Non-adherence                                                 | 6 (9%) | 3 (5%) | 9 (7%) |
| Temporary break                                               | 3 (5%) | 5 (8%) | 8 (6%) |
| Unknown                                                       | 5 (8%) | 1 (2%) | 6 (5%) |
| Drug supply problem                                           | 1 (2%) | 2 (3%) | 3 (2%) |
| Intercurrent illness                                          | 0 (0%) | 2 (3%) | 2 (2%) |
| Resistance                                                    | 1 (2%) | 1 (2%) | 2 (2%) |
| Parent forgot                                                 | 1 (2%) | 0 (0%) | 1 (1%) |
| Simplification                                                | 0 (0%) | 1 (2%) | 1 (1%) |
| Treatment record total                                        | 65   | 61    | 126   |
| Adherence Questionnaire<sup>b</sup>                           |     |       |       |
| Forgot/lack of support                                        | 10 (29%) | 10 (30%) | 20 (30%) |
| Ran out of drug                                               | 8 (24%) | 9 (27%) | 17 (25%) |
| Problems taking some of the drugs (e.g., intolerance, taste, medication volume) | 11 (32%) | 5 (15%) | 16 (24%) |
| Fear of disclosure to others                                  | 10 (29%) | 5 (15%) | 15 (22%) |
| Patient refused/didn’t want to take drugs                     | 10 (29%) | 4 (12%) | 14 (21%) |
| Scheduling/lifestyle interference                              | 9 (26%) | 3 (9%) | 12 (18%) |
| Drug toxicity concerns                                        | 7 (21%) | 4 (12%) | 11 (16%) |
| Supervised by someone else or multiple caregivers             | 6 (18%) | 5 (15%) | 11 (16%) |
| Patient unwell                                                | 6 (18%) | 4 (12%) | 10 (15%) |
| Other                                                         | 4 (12%) | 5 (15%) | 9 (13%) |
| Different routine/change in living situation                  | 3 (9%) | 4 (12%) | 7 (10%) |
| Fed up giving/taking drugs                                    | 3 (9%) | 2 (6%) | 5 (7%) |
| Think medication is not needed or not helping                 | 2 (6%) | 2 (6%) | 4 (6%) |
| Caregiver unwell/depressed                                    | 0 (0%) | 0 (0%) | 0 (0%) |
| Total listed problems on questionnaire<sup>b</sup>             | 89   | 62    | 151   |
| Total participants with questionnaire-reported missed doses     | 34   | 33    | 67    |
| Total Treatment Disruption Events<sup>c</sup>                 | 97   | 94    | 191   |

<sup>a</sup> One category allowed per treatment record change or stop.
<sup>b</sup> Participants may have answered in more than one category.
<sup>c</sup> Some participants had both a treatment record and adherence questionnaire event at the same time.

n, subsample size or number of events; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor.

https://doi.org/10.1371/journal.pone.0242405.t002
forgetting/lack of support and running out of drug. Novel interventions may still be able to improve the experience of drug administration. Pediatric pellets are heat-stable and generally more acceptable than syrups, but palatability and administration problems persist and may increase over time [61–63]. Pediatric granules, especially in the four-in-one combination, may improve palatability and decrease pill burden [35, 64]. Precision medicine related to taste-sensing genotypes may hold promise for prescribing according to individualized palatability [65]. In adult data, integrase strand transferase inhibitors (INSTIs) have been at least as tolerable as PIs or NNRTIs, if not more so, and INSTIs are increasingly preferred drugs in children [66–69]. Nevertheless, a primary goal of optimizing continuous therapy to ART is durable viral suppression, which was comparable across PI vs. NNRTI arms in this study’s parent trial, although similar trials had variable results [23, 70–74]. In this study population, choice of either PI- or NNRTI-based initial ART appears acceptable.

Our estimates of treatment disruption may have had measurement error. First, we had no direct measures of drug exposure, such as therapeutic drug monitoring. Treatment records captured only prescribing events and documented ART disruptions, and the adherence questionnaires relied on accurate reporting by either the child or the caregiver, if present and willing to answer. Although we relied on a questionnaire that has previously been validated [24], reporting biases and unanswered questionnaires may have affected our measures of missed doses. Our combining treatment records and adherence questionnaires into a composite outcome should have decreased measurement error from either instrument individually. Second, adherence questionnaires in this study focused on ART adherence over the 3 days prior to the most recent visit and inquired about adherence barriers encountered over the prior 2 weeks, rather than a daily measure of adherence throughout the study. The time-varying nature of treatment disruption means that patients may have experienced an initial or temporary period of treatment disruption that was subsequently corrected [75, 76], but our analysis presents only data on time to first event of treatment disruption. Third, limited participant report of individual drugs missed on the adherence questionnaire precluded definitive identification of treatment disruptions of individual drugs. Instead, we assessed treatment disruption to any component of the ART regimen. Fourth, heterogeneity of adherence questionnaires across networks, ages, and respondents regarding barriers to therapy should caution against rigorous interpretation of reasons for treatment disruptions. Finally, this study size was not sufficient to distinguish differences on the order of 7%, as was seen at 4 years.

Conclusions
In conclusion, children in PENPACT-1 had similar time to treatment disruption for initial PI-based regimens and NNRTI-based regimens. Although secondary analyses suggest that PI-based regimens may be more difficult to tolerate and may be less convenient to administer, these difficulties did not result in a large difference in children stopping, changing, or missing doses at 4 years (PI 70%, NNRTI 63%), and any suggested differences diminished by study end (PI 81%, NNRTI 84%). Initial ART with either a PI or NNRTI may be acceptable for maintaining continuous therapy on ART in children.

Supporting information
S1 Checklist. CONSORT checklist.
(DOC)

S1 Protocol. PENPACT-1 trial protocol.
(PDF)
Acknowledgments

The PENPACT-1 (PENTA 9 / PACTG 390) study team

PENPACT-1 protocol team. PACTG/IMPAACT/NICHDD: P Brouwers, D Costello, E Ferguson, S Fiscus, J Hodge, M Hughes, C Jennings, A Melvin (Co-Chair), R McKinney (Co-Chair), L Mofenson, M Warshaw, ME Smith, S Spector, E Stiehm, M Toye, R Yoge.v.

PENTA: JP Aboulker, A Babiker, H Castro, A Compagnucci, A De Rossi, C Giaquinto, J Darbyshire, M Debré, DM Gibb, L Harper, L Harrison, N Klein, D Pillay, Y Saidi, G Tudor-Williams (Co-Chair), AS Walker.

Data and Safety Monitoring Board: B Brody, C Hill, P Lepage, J Modlin, A Poziak, M Rein (Chair 2002–2003), M Robb (Chair 2004–2009), T Fleming, S Vella, K Kim.

Clinical sites (L = lab, P = pharmacy). Argentina: Hospital de Pediatría Dr JP Garrahan, Buenos Aires: R Bologna, D Mecikovsky, N Pineda, L Sen (L), A Mangano (L), S Marino (L), C Galvez (L); Laboratorio Fundai: G Deluchi (L).

Austria: Universtätshuhn für Kinder und Jugendheilkunde, Graz: B Zörer, W Zenz, E Doghofer, K Pfurtscheller, B Pabst (L).

Bahamas: Princess Margaret Hospital: MP Gomez, P McNeil, M Jervis, I Whyns, D Kwolfe, S Scott (P).

Brazil: University of Sao Paulo at Ribeirao Preto: MM Mussi-Pinhata, ML Issac, MC Cervi, BVM Negrini, TC Matsubara, C BSS de Souza (L), JC Gabaldi (P); Institute of Pediatrics (IIPPMG), Federal University of Rio de Janeiro: RH Oliveira, MC Sapia, T Abreu, L Evangelista, A Pala, I Fernandes, I Farias, M de F Melo (L), H Carreira (P), LM Lira (P); Instituto de Infectologia Emilio Ribas, Sao Paolo: M della Negra, W Queiroz, YC Lian; DP Pacola; Fleury Laboratories; Federal University of Minas Gerais, Belo Horizonte: J Pinto, F Ferreira, F Kakehadi, L Martins, A Diniz, V Lobato, M Diniz, C Hill (L), S Cleto (L), S Costa (P), J Romeir (P).

France: Hôpital d’enfants Armand Trousseau, Paris: C Dollfus, MD Tabone, MF Courcoux, G Vaudre A Dehée (L), A Schnuriger (L), N Le Gueyades (P), C De Bortoli (P); CHU Hôtel Dieu, Nantes: F Méchiraudin, V Reliquet, J Arias (L), A Rodallec (L), E André (L), I Falconi (P), A Le Pelletier (P); Hôpital de l’Archet II, Nice, F Monpoux, J Cottalorda (L), S Mellul (L); Hôpital Jean Verdier, Bondy: E Lachassinne; Laboratoire de virologie-Hôpital Necker Enfants Malades, Paris: J Galimand (L), C Rouzioux (L), ML Chaix (L), Z Benabadj (P), M Pourrat (P); Hôpital Cochin Port-Royal- Saint Vincent de Paul, Paris: G Firtion, D Rivaux, M Denon, N Boudjoudi, F Nganzali, A Krivine (L), JF Meritet (L), G Delommois (L), C Nogeux (L), C Guérin (P); Hôpital Louis Mourier, Colombes: C Floch, L Marty, H Hichou (L), V Tourin (P); Hôpital Robert Debré, Paris: A Faye, I Le Moal, M Seller (P), L Dehache (P); Laboratoire de virologie-Hôpital Bichat Claude Bernard-Paris: F Damond (L), J Leleu (L), D Beniken (L), G Alexandre-Castor (L).

Germany: Universitäts-Kinderklinik Düsseldorf: J Neubert, T Niehues, HJ Laws, K Huck, S Gudowius, K Siepermann, H Loeffler, S Bellert (L), A Ortwin (L); Universitäts-Kinderkliniken, Munich: G Noltheis, U Wintergerst, F Hoffman, A Werthmann, S Seyboldt, L Schneider, B Buchholz; Charité-Medizische Fakultät der Humboldt-Universität zu Berlin: C Feiterna-Sperling, C Peiser, R Nickel, T Schmitz, T Piening, C Müller (L); Kinder und Jugendklinik, Universität Rostock: G Warncke, M Wigger, R Neubauer.

Ireland: Our Lady’s Children’s Hospital Crumlin, Dublin: K Butler, AL Chong, T Boulger, A Menon, M O’Connell, L Barrett, A Rochford, M Goode, E Hayes, S McDonagh, A Walsh, A Doyle, J Fanning (P), M O’Connor (P), M Byrne (L), N O’Sullivan (L), E Hyland (L).

Italy: Clinica Pediatrica, Ospedale L Sacco, Milan: V Giacomet, A Viganò, I Colombo, D Trabattoni (L), A Berzi (L); Clinica Pediatrica, Università di Brescia: R Badolato, F Schumacher, V Bennato, M Brusati, A Sorlini, E Spinelli, M Filisetti, C Bertulli; Clinica Pediatrica,
Università di Padova: O Rampon, C Giaquinto, M Zanchetta (L); Ospedale S. Chiara, Trento: A Mazza, G Stringari, G Rossetti (L); Ospedale del Bambino Gesù, Rome: S Bernardi, A Martino, G Castelli Gattinara, P Palma, G Pontrelli, H Tchidjou, A Furcas, C Frillici, A Mazzei, A Zoccano (P), C Concato (L).

Romania: Spitalul Clinic de Boli Infectioase Victor Babes, Bucharest: D Duiculescu, C Oprea, G Tardei (L), F Aabaab (P); Institutul de Boli Infectioase Matei Bals, Bucharest: M Marinescu, R Draghicienoiu, D Otelea (L), I. Alecsandru (P); Clinic Municipal, Constanta: R Matusa, S Rугина, M Ilie, Silvia Netescu (P). Clinical monitors: C Florea, E Voicu, D Poalelungi, C Belmega, L Vladau, A Chiriac.

Spain: Hospital Materno-Infantil 12 de Octubre, Madrid: JT Ramos Amador, MI Gonzalez Tomé, P Rojo Conejo, M Fernandez, R Delgado Garcia (L), JM Ferrari (P); Institute de Salud Carlos III, Madrid: M Garcia Lopez, MJ Mellado Peña, P Martin Fontelos, I Jimenez Nacher (P); Biobanco Gregorio Marañon, Madrid: MA Muñoz Fernandez (L), JL Jimenez (L), A Garcia Torre (L); clinical monitors: M Penin, R Pineiro Perez, I Garcia Mellado.

UK: Bristol Royal Children’s Hospital: A Finn, M Lajeunesse, E Hutchison, J Usher (L), L Ball (P), M Dunn (P); St. George’s Healthcare NHS Trust, London: M Sharland, K Doehert, S Storey, S Donaghy, R Chakraborty, C Wells (P), K Buckberry (P), P Rice (P); University Hospital of North Staffordshire: P McMaster, P Butler, C Farmer (L), J Shenton (P), H Haley (P), J Orendi (L), University Hospital Lewisham: J Stroobant, L Navarante, P Archer, C Mazhude, D Scott, R O’Connell, J Wong (L), G Boddy (P); Sheffield Children’s Hospital: F Shackley, R Lakshman, J Hobbs, G Ball (L), G Kudesia (L), J Bane (P), D Painter (P); Ealing Hospital NHS Trust: K Sloper, V Shah, A Cheng (P), A Aali (L); King’s College Hospital, London: C Ball, S Hawkins, D Nayagam, A Waters, S Doshi (P); Newham University Hospital: S Liebeschuetz, B Sodienne, D Shingadia, S Wong, J Swan (P), Z Shah (P); Royal Devon and Exeter Hospital: A Collinson, C Hayes, J King (L), K O’Connor (L); Imperial College Healthcare NHS Trust, London: G Tudor-Williams, H Lyall, K Fidler, S Walters, C Foster, D Hamadache, C Newbould, C Monrose, S Campbell, S Yeung, J Cohen, N Martinez-Allier, D Melvin, J Dodge, S Welch, G Tatum, A Gordon, S Kaye (L), D Muir (L), D Patel (P); Great Ormond Street Hospital: V Novelli, D Gibb, D Shingadia, K Moshal, J Lambert, N Klein, J Flynn, L Farrelly, M Clapson, L Spencer, M Depala (P); Institute of Child Health, London: M Jacobsen (L); John Radcliffe Hospital, Oxford: S Segal, A Pollard, D Kelly, S Yeaden, B Ohene-Kena Y Peng (L), T Dong (L), Y Peng (L), K Jeffries (L), M Snelling (P), Nottingham University Hospitals: A Smyth, J Smith; Chelsea and Westminster Hospital, London: B Ward; Mortimer Market Centre, London: E Jungmann; Doncaster Royal Infirmary: C Ryan, K Swaby; Health Protection Agency, London: A Buckton (L); Health Protection Agency, Birmingham: E Smit (L).

USA: Harlem Hospital Center: EJ Abrams, S Champion, AD Fernandez, D Calo, L Garrovillo, K Swaminathan, T Alford, M Frere, Columbia University Laboratories, J Navarra (P, Town Total Health); NYU School of Medicine: W Borkowsky, S Deygoo, T Hastings, S Akleh, T Ilmet (L); Seattle Children’s Hospital: A Melvin, K Mohan, G Bowen (Additional support by NIH Grant UL1 RR025014); University of South Florida: PJ Emmanuel, J Lujan-Zimmerman, C Rodriguez, S Johnson, A Marion, C Graisbery, D Casey, G Lewis; All Children’s Hospital Laboratories; Oregon Health and Science University: J Guzman-Cottrill, R Croteau; San Juan City Hospital: M Acevedo-Flores, M Gonzalez, I Angeli; L Fabregas, Lab 053, P Valentín (P); SUNY- Upstate Medical University-Syracuse: L Weiner, KA Contello, W Holz, M Butler; SUNY, Health Science Center at Stonybrook: S Nachman, MA Kelly, DM Ferraro, UNC Retrovirology Lab; Howard University Hospital: S Rana, C Reed, R Yeagle, A Malheiro, J Roa; LAC and USC Medical Center: M Neely, A Kovacs, L Spencer, J Homans, Y Rodriguez Lozano, Maternal Child Virology Research Laboratory, Investigational Drug Service; South Florida Children’s Diagnostic & Treatment Center: A Puga, G Talero, R Sellers; Broward
General Medical Center, University of Miami (L); University College of Florida College of Medicine-Gainesville: R Lawrence; University of Rochester Pediatrics: GA. Weinberg, B Murante, S Laverty; Miller Children’s Hospital Long Beach: A Deveikis, J Batra, T Chen, D Michaliak, J Deville, K Elkins, S Marks, J Jackson Alvarez, J Palm, I Fineangelofo (L), M Keuth (L), L Deveikis (L), W Tomosada (P); Tulane University New Orleans: R Van Dyke, T Alchediak, M Silio, C Borne, S Bradford, S Eloby-Childress (L), K Nguyen (P); University of Florida/Jacksonville: MH Rathore, A Alvarez; A Mirza, S Mahmoudi, M Burke; University of Puerto Rico: IL Febo, L Lugo, R Santos; Children’s Hospital Los Angeles: JA Church, T Dunaway, C Rodier; St. Jude/UTHSC: P Flynn, N Patel, S DiScenza, M Donofoe; WNE Maternal Pediatric Adolescent AIDS: K Luzuriaga, D Picard; Texas Children’s Hospital: M Kline, ME Paul, WT Shearer, C McMullen-Jackson; Children’s Memorial Hospital, Chicago: R Yogev, E Chadwick, E Cagwin, K Kabat; New Jersey Medical School: A Dieudonne, P Palumbo, J Johnson; Robert Wood Johnson Medical School, New Brunswick: S Gaur, L Cerracchio; Columbia IMPAACT: M Foca, A Jurgrau, S Vasquez Bonilla, G Silva; Babies’ Hospital, Columbia/Presbyterian Medical Center, New York: A Gershon; University of Massachusetts Medical Center, Worcester: J Sullivan; UCLA Medical Center, Los Angeles: Y Bryson; Children’s Hospital, Seattle: L Frenkel; UNC-Chapel Hill Virology Lab: S Fiscus (L), J Nelson (L).

**Trials units/support.** INSERM SC10 Paris: JP Aboulker, A Compagnucci, G Hadjou, S Léonardo, Y Riault, Y Saïdi.

MRC Clinical Trials Unit, UK: A Babiker, L Buck, JH Darbyshire, I Farrelly, S Forcat, DM Gibb, H Castro, L Harper, I Harrison, J Horton, D Johnson, S Moore, C Taylor, AS Walker.

Westat/NICHD: D Collins, S Buskirk, P Kamara, C Nesel, M Johnson, A Ferreira.

Frontier Science: J Hodge, J Tutko, H Sprenger.

IMPAACT: M Hughes, M Warshaw, P Britto, C Powell.

NIAID: R DerSimonian, E Handelsman (deceased).

PENTA Steering Committee: JP Aboulker, J Ananworanich, A Babiker, E Belfrage, S Bernardi, S Blanche, AB Bohlin, R Bologna, D Burger, K Butler, G Castelli-Gattinara, H Castro, P Clayden, A Compagnucci, JH Darbyshire, M Debré, R De Groot, M Della Negra, A De Rossi, A Di Biagio, D Duiculescu, A Faye, V Giacomet, C Giaquinto (Chair), DM Gibb, I Grosch-Wörner, M Hainault, L Harper, N Klein, M Lallemant, J Levy, H Lyall, M Marczynska, M Mardearscu, MJ Mellado Pena, D Nadal, L Naver, T Niehues, C Peckham, D Pillay, J Popieska, JT Ramos Amador, L Rosado, R Rosso (deceased), C Rudin, Y Saïdi, H Scherpier, M Sharland, M Stevanovic, C Thorne, PA Tovo, G Tudor-Williams, AS Walker, S Welch, U Wintergerst, N Valerius.

**Participants, families, and staff**

We thank all the children, families, and staff from the centers participating in the PEPFAR-PACT-1 trial. We thank the Children’s Mercy Medical Writing Center for copyediting this document.

**Author Contributions**

**Conceptualization:** Dwight E. Yin, Stephen R. Cole, Meredith G. Warshaw, Ross E. McKinney, Jr.

**Data curation:** Dwight E. Yin, Christina Ludema, Meredith G. Warshaw.

**Formal analysis:** Dwight E. Yin, Christina Ludema.

**Funding acquisition:** Ross E. McKinney, Jr.

**Investigation:** Ross E. McKinney, Jr.
Methodology: Dwight E. Yin, Stephen R. Cole, Carol E. Golin, William C. Miller, Meredith G. Warshaw, Ross E. McKinney, Jr.

Project administration: Dwight E. Yin, Stephen R. Cole, Ross E. McKinney, Jr.

Resources: Dwight E. Yin.

Software: Dwight E. Yin.

Supervision: Stephen R. Cole, Ross E. McKinney, Jr.

Validation: Dwight E. Yin, Christina Ludema.

Visualization: Dwight E. Yin, Christina Ludema.

Writing – original draft: Dwight E. Yin.

Writing – review & editing: Dwight E. Yin, Christina Ludema, Stephen R. Cole, Carol E. Golin, William C. Miller, Meredith G. Warshaw, Ross E. McKinney, Jr.

References

1. Joint United Nations Programme on HIV/AIDS. UNAIDS Data 2018. Geneva, Switzerland: UNAIDS; 2018 [cited 2019 Jun 21]. Available at: https://www.unaids.org/sites/default/files/media_asset/unaids-data-2018_en.pdf.

2. Van der Linden D, Callens S, Brichard B, Colebunders R. Pediatric HIV: new opportunities to treat children. Expert Opin Pharmacother. 2009; 10(11):1783–91. https://doi.org/10.1517/14656560903012377 PMID: 19558340

3. Brichard B, Van der Linden D. Clinical practice treatment of HIV infection in children. Eur J Pediatr. 2009; 168(4):387–92. https://doi.org/10.1007/s00431-008-0914-8 PMID: 19152000

4. Leonard EG, McComsey GA. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival. Infect Dis Clin North Am. 2005; 19(3):713–29. https://doi.org/10.1016/j.idc.2005.05.006 PMID: 16102657

5. Leonard EG, McComsey GA. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J. 2003; 22(1):77–84. https://doi.org/10.1097/00002030-200301000-00018 PMID: 12544413

6. Mellins CA, Brackis-Cott E, Dolezal C, Abrams EJ. The role of psychosocial and family factors in adherence to antiretroviral treatment in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2004; 23(11):1035–41. https://doi.org/10.1097/00002030-200411000-00018 PMID: 15545859

7. Buchanan AL, Montepiedra G, Sirois PA, Kammerer B, Garvie PA, Storm DS, et al. Barriers to medication adherence in HIV-infected children and youth based on self- and caregiver report. Pediatrics. 2012; 129(5):e1244–51. https://doi.org/10.1542/peds.2011-1740 PMID: 22508915

8. Dabis F, Elenga N, Meda N, Leroy V, Viho I, Manigart O, et al. 18-Month mortality and perinatal exposure to zidovudine in West Africa. AIDS. 2001; 15(6):771–9. https://doi.org/10.1097/00002030-200104130-00018 PMID: 11371692

9. Violori A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008; 359(21):2233–44. https://doi.org/10.1056/NEJMoa0800971 PMID: 19020325

10. Becquet R, Marston M, Dabis F, Moulton LH, Gray G, Coovadia HM, et al. Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis. PLoS One. 2012; 7(2):e28510. https://doi.org/10.1371/journal.pone.0028510 PMID: 22283946

11. Edessa D, Sisay M, Asefa F. Second-line HIV treatment failure in sub-Saharan Africa: A systematic review and meta-analysis. PLoS One. 2019; 14(7):e0220159. https://doi.org/10.1371/journal.pone.0220159 PMID: 31356613

12. Pham PA. Antiretroviral adherence and pharmacokinetics: review of their roles in sustained virologic suppression. AIDS Patient Care STDs. 2009; 23(10):803–8. https://doi.org/10.1089/apc.2008.0269 PMID: 19795999

13. Gross R YB, Wood E, Bangsberg D, Justice AC, Montaner JS. Boosted PIs are more forgiving of suboptimal adherence than nonboosted PIs or NNRTIs. 13th Conference on Retroviruses and Opportunistic Infections; Denver, CO, USA; 2006.
14. Harrison L, Melvin A, Fiscus S, Saidi Y, Nastouli E, Harper L, et al. HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds. J Acquir Immune Defic Syndr. 2015; 70(1):42–53. https://doi.org/10.1097/QAI.0000000000000671 PMID: 26322666

15. Agwu A, Lindsey JC, Ferguson K, Zhang H, Specter S, Rudy BJ, et al. Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy. AIDS Patient Care STDS. 2008; 22(7):545–52. https://doi.org/10.1089/apc.2007.0200 PMID: 18479228

16. Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, Harrigan PR, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006; 20(2):223–31. https://doi.org/10.1097/01.aids.0000199825.34241.49 PMID: 16511415

17. Muller AD, Myer L, Jaspan H. Virological suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy. Clin Infect Dis. 2009; 48(1):e3–5. https://doi.org/10.1086/595553 PMID: 19025495

18. Davies MA, Boulle A, Fakir T, Nuttall J, Eley B. Adherence to antiretroviral therapy in young children in Cape Town, South Africa, measured by medication return and caregiver self-report: a prospective cohort study. BMC Pediatr. 2008; 8:34. https://doi.org/10.1186/1471-2431-8-34 PMID: 18771599

19. Esteban Gomez MJ, Escobar Rodriguez I, Vicario Zubizarreta MJ, Climente Pollan J, Herreros de Tejada A. [Influence of antiretroviral therapy characteristics on pediatric patient adherence]. Farmacia. Hosp. 2004; 28(6 Suppl 1):34–9. PMID: 15649114

20. Lin D, Seabrook JA, Matsui DM, King SM, Rieder MJ, Finkelstein Y. Palatability, adherence and prescribing patterns of antiretroviral drugs for children with human immunodeficiency virus infection in Canada. Pharmacoeconomics Drug Saf. 2011; 20(12):1246–52. https://doi.org/10.1002/pds.2236 PMID: 21936016

21. Blatt Soffer D, Zembaty J, Gines A, Ariel T, Pfeiffer E, Green H, et al. Teaching and maintaining pill swallowing in HIV-infected children. J Acquir Immune Defic Syndr. 2005; 40(4):498–500. https://doi.org/10.1097/01.qai.0000168180.76405.5f PMID: 16280708

22. Giacomet V, Albano F, Starace F, de Franciscis A, Giaquinto C, Gattinara GC, et al. Adherence to antiretroviral therapy and its determinants in children with human immunodeficiency virus infection: a multicentre, national study. Acta Paediatr. 2003; 92(12):1398–402. https://doi.org/10.1080/0803525031006737 PMID: 14971789

23. Czyzewski D RD, Lopez M, et al. Teaching and maintaining pill swallowing in HIV-infected children. AIDS Read. 2000; 10(2):88–94.

24. Garvie PA, Lensing S, Rai SN. Efficacy of a pill-swallowing training intervention to improve antiretroviral medication adherence in pediatric patients with HIV/AIDS. Pediatrics. 2007; 119(4):e893–9. https://doi.org/10.1542/peds.2006-1488 PMID: 17353298

25. Elise A, France AM, Louise WM, Bata D, Francois R, Roger S, et al. Assessment of adherence to highly active antiretroviral therapy in a cohort of African HIV-infected children in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr. 2000; 23(3):252–6. https://doi.org/10.1097/00015921-200004000-00008 PMID: 10742032

26. Van Dyke RB, Lee S, Johnson GM, Wiznia A, Mohan K, Stanley K, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics. 2002; 109(4):e61. https://doi.org/10.1542/peds.109.4.e61 PMID: 11927734

27. Bhattacharya M, Dubey AP. Adherence to antiretroviral therapy and its correlates among HIV-infected children at an HIV clinic in New Delhi. Ann Trop Paediatr. 2011; 31(4):331–7. https://doi.org/10.1179/1465328111Y.0000000031 PMID: 22041467

28. Elise A, France AM, Louise WM, Bata D, Francois R, Roger S, et al. Assessment of adherence to highly active antiretroviral therapy in a cohort of African HIV-infected children in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr. 2000; 23(3):252–6. https://doi.org/10.1097/00015921-200004000-00008 PMID: 10742032

29. Garvie PA, Lensing S, Rai SN. Efficacy of a pill-swallowing training intervention to improve antiretroviral medication adherence in pediatric patients with HIV/AIDS. Pediatrics. 2007; 119(4):e893–9. https://doi.org/10.1542/peds.2006-1488 PMID: 17353298

30. Maggio F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, Arici C, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005; 40(1):158–63. https://doi.org/10.1086/426595 PMID: 15614706

31. Kapadia SN, Grant RR, German SB, Singh B, Davidow AL, Swaminathan S, et al. HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens.
32. Clay PG, Nag S, Graham CM, Narayanan S. Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment Regimens. Medicine. 2015; 94(42):e1677. https://doi.org/10.1097/MD.0000000000001677 PMID: 24457345

33. Nachega JB, Parienti JJ, Uthman OA, Gross R, Dowdy DW, Sax PE, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis. 2014; 58(9):1297–307. https://doi.org/10.1093/cid/ciu046 PMID: 24457345

34. PantuZZa LL, Ceccato M, Silveira MR, Junqueira LMR, Reis AMM. Association between medication regimen complexity and pharmacotherapy adherence: a systematic review. Eur J Clin Pharmacol. 2017; 73(11):1475–89. https://doi.org/10.1007/s00228-017-2315-2 PMID: 28779460

35. Penazzato M, Townsend CL, Rakhmanina N, Cheng Y, Archary M, Cressey TR, et al. Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list. Lancet HIV. 2019; 6(9):e623–e631. https://doi.org/10.1016/S2352-3018(19)30193-6 PMID: 31498110

36. Barro M, Some J, Fouloungne V, Diasso Y, Zoure E, Hien H, et al. Short-term virological efficacy, immune reconstitution, tolerance, and adherence of once-daily dosing of didanosine, lamivudine, and efavirenz in HIV-1-infected African children: ANRS 12103 Burkiname. J Acquir Immune Defic Syndr. 2011; 57 Suppl 1:S44–9.

37. Biadgilign S, Deribew A, Amberbir A, Deribe K. Barriers and facilitators to antiretroviral medication adherence among HIV-infected paediatric patients in Ethiopia: A qualitative study. SAHARA J. 2009; 6(4):148–54. https://doi.org/10.1080/17290376.2009.9724943 PMID: 20485854

38. Brackis-Cott E, Mellins CA, Abrams E, Reval T, Dolezal C. Pediatric HIV medication adherence: the views of medical providers from two primary care programs. J Pediatr Health Care. 2003; 17(5):252–60. https://doi.org/10.1016/s0891-5245(02)88313-4 PMID: 14576630

39. Buscher A, Hartman C, Kallen MA, Giordano TP. Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients. Int J STD AIDS. 2012; 23(5):351–5. https://doi.org/10.1258/ij sa.2011.011292 PMID: 22648890

40. Fortuin-de Smidt M, de Waal R, Cohen K, Technau KG, Stinson K, Maartens G, et al. First-line antiretroviral drug discontinuations in children. PLoS One. 2017; 12(2):e0169762. https://doi.org/10.1371/journal.pone.0169762 PMID: 28192529

41. Germanaud D, Derache A, Traore M, Maedec Y, Toure S, Dicko F, et al. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor-first-line treatment in HIV-1-infected children in Mali. J Antimicrob Chemother. 2010; 65(1):118–24. https://doi.org/10.1093/jac/dkp412 PMID: 19933171

42. Patten G, Schomaker M, Davies MA, Rabie H, van Zyl G, Techau K, et al. What Should We Do When HIV-positive Children Fail First-line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies. Pediatr Infect Dis J. 2019; 38(4):400–5. https://doi.org/10.1097/INF.0000000000002156 PMID: 30882732

43. Chen TK, Aldrovandi GM. Review of HIV antiretroviral drug resistance. Pediatr Infect Dis J. 2008; 27(8):749–52. https://doi.org/10.1097/INF.0b013e3181846e2e PMID: 18664897

44. Germanaud D, Derache A, Traore M, Maedec Y, Toure S, Dicko F, et al. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor-first-line treatment in HIV-1-infected children in Mali. J Antimicrob Chemother. 2010; 65(1):118–24. https://doi.org/10.1093/jac/dkp412 PMID: 19933171

45. Patten G, Shomaker M, Davies MA, Rabie H, van Zyl G, Techau K, et al. What Should We Do When HIV-positive Children Fail First-line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies. Pediatr Infect Dis J. 2019; 38(4):400–5. https://doi.org/10.1097/INF.0000000000002156 PMID: 30882732

46. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. New Engl J Med. 2016; 375(9):830–9. https://doi.org/10.1056/NEJMoa1600693 PMID: 27424812

47. Flynn PM, Rudy BJ, Douglas SD, Lathey J, Spector SA, Martinez J, et al. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis. 2004; 190(2):271–9. https://doi.org/10.1086/421521 PMID: 15216461

48. Flynn PM, Rudy BJ, Lindsay JC, Douglas SD, Lathey J, Spector SA, et al. Long-term observation of adolescents initiating HAART therapy: three-year follow-up. AIDS Res Hum Retroviruses. 2007; 23(10):1208–14. https://doi.org/10.1089/aids.2006.0290 PMID: 17961106
50. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007; 4(2):65–72. https://doi.org/10.1007/s11904-007-0010-0 PMID: 17547827

51. Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS. 2009; 23(9):1035–46. https://doi.org/10.1097/QAD.0b013e32832ba8ec PMID: 19381075

52. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006; 43(7):939–41. https://doi.org/10.1086/507526 PMID: 16941380

53. Magniolo F, Airoldi M, Kleinloog HD, Callegaro A, Ravasio V, Arici C, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials. 2007; 8(5):282–92. https://doi.org/10.1310/htct0805-282 PMID: 17956829

54. Golin CE, Liu H, Hays RD, Miller LG, Beck CK, Ickovics J, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Intern Med. 2002; 17(10):756–65. https://doi.org/10.1046/j.1525-1497.2002.11214.x PMID: 12390551

55. Bangsberg DR, Deeks SG. Is average adherence to HIV antiretroviral therapy enough? J Gen Intern Med. 2002; 17(10):812–3. https://doi.org/10.1046/j.1525-1497.2002.20812.x PMID: 13905559

56. Gross R, Biker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001; 15(16):2109–17. https://doi.org/10.1097/00002030-200111090-00006 PMID: 11684930

57. De Rossi A. Virological and immunological response to antiretroviral therapy in HIV-1 infected children: genotypic and phenotypic assays in monitoring virological failure. New Microbiol. 2004; 27(2 Suppl 1):45–50. PMID: 15646064

58. Filho LF, Nogueira SA, Machado ES, Abreu TF, de Oliveira RH, Evangelista L, et al. Factors associated with lack of antiretroviral adherence among adolescents in a reference centre in Rio de Janeiro, Brazil. Int J STD AIDS. 2008; 19(10):685–8. https://doi.org/10.1258/ij.sja.2008.008017 PMID: 18824621

59. Foster C, Fidler S. Optimizing antiretroviral therapy in adolescents with perinatally acquired HIV-1 infection. Expert Rev Anti Infect Ther. 2010; 8(12):1403–16. https://doi.org/10.1586/eri.10.129 PMID: 21133665

60. Kacanek D, Hsueh RD, Miller LG, Beck CK, Ickovics J, et al. Nonadherence and unsuppressed viral load across adolescence among US youth with perinatally acquired HIV. AIDS. 2019; 33(12):1923–34. https://doi.org/10.1097/QAD.000000000002301 PMID: 31274538

61. Kekitiinwa A, Musiime V, Thomason MJ, Mirembe G, Lallemant M, Nakalanzi S, et al. Acceptability of lopinavir/ritonavir pellets (minitabs), tablets and syrups in HIV-infected children. Antivir Ther. 2016; 21(7):579–85S. https://doi.org/10.3851/IMP3054 PMID: 27128199

62. Pasipanodya B, Kuwenga R, Prust ML, Stewart B, Chakanyuka C, Murirwa T, et al. Assessing the adoption of lopinavir/ritonavir oral pellets for HIV-positive children in Zimbabwe. J Int AIDS Soc. 2018; 21(12):e25214. https://doi.org/10.1002/jia2.25214 PMID: 30549217

63. Giralt AN, Nöstlinger C, Lee J, Salami O, Lallemant M, Onyango-Ouma W, et al. Understanding acceptance of and adherence to a new formulation of paediatric antiretroviral treatment in the form of pellets (LPV/r)-A realistic evaluation. PLoS One. 2019; 14(8):e0220408. https://doi.org/10.1371/journal.pone.0220408 PMID: 31433803

64. Pham K, Li D, Guo S, Penzak S, Dong X. Development and in vivo evaluation of child-friendly lopinavir/ritonavir pediatric granules utilizing novel in situ self-assemble nanoparticles. J Control Release. 2016; 226:88–97. https://doi.org/10.1016/j.jconrel.2016.02.001 PMID: 26849919

65. Mennella JA, Mathew PS, Lowenthal ED. Use of Adult Sensory Panel to Study Individual Differences in the Palatability of a Pediatric HIV Treatment Drug. Clin Ther. 2017; 39(10):2038–48. https://doi.org/10.1016/j.clinthera.2017.08.012 PMID: 28923290

66. Lennox JL, DeJesus E, Lazzarini A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009; 374(9692):796–806. https://doi.org/10.1016/S0140-6736(09)60918-1 PMID: 19647866

67. Molina JM, Clotet B, van Lunzen J, Lazzarini A, Cavassini M, Henry K, et al. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naive HIV-1-positive individuals: 96 week results from FLAMINGO. J Int AIDS Soc. 2014; 17(4 Suppl 3):19490. https://doi.org/10.7448/IAS.17.4.19490 PMID: 25393999

68. Snedecor SJ, Radford M, Kratochvil D, Grove R, Punekar YS. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naive patients infected with HIV-1: a
systematic review and network meta-analysis. BMC Infect Dis. 2019; 19(1):484. https://doi.org/10.1186/s12879-019-3975-6 PMID: 31146698

69. Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection [cited 2019 Nov 27]. Available from: http://aidsinfo.nih.gov/contentfiles/pediatricguidelines.pdf.

70. Coovadia A, Abrams EJ, Stehlaü R, Meyers T, Martens L, Sherman G, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA. 2010; 304(10):1082–90. https://doi.org/10.1001/jama.2010.1278 PMID: 20823434

71. Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, Kamthunzi P, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med. 2012; 366(25):2380–9. https://doi.org/10.1056/NEJMoa1113249 PMID: 22716976

72. Ruel TD, Kakuru A, Ikilezi G, Mwangwa F, Dorsey G, Rosenthal PJ, et al. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr. 2014; 65(5):535–41. https://doi.org/10.1097/QAI.0000000000000071 PMID: 24326597

73. Barlow-Mosha L, Angelidou K, Lindsey J, Archary M, Cotton M, Dittmer S, et al. Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial. Clin Infect Dis. 2016; 63(8):1113–21. https://doi.org/10.1093/cid/ciw488 PMID: 27439527

74. Murnane PM, Stehlaü R, Shiau S, Patel F, Mbete N, Hunt G, et al. Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial. Clin Infect Dis. 2017; 65(3):477–85. https://doi.org/10.1093/cid/cix335 PMID: 28419200

75. Byakika-Tusiime J, Crane J, Ouyi JH, Ragland K, Kawuma A, Musoke P, et al. Longitudinal antiretroviral adherence in HIV+ Ugandan parents and their children initiating HAART in the MTCT-Plus family treatment model: role of depression in declining adherence over time. AIDS Behav. 2009; 13 Suppl 1:82–91. https://doi.org/10.1007/s10461-009-9546-x PMID: 19301115

76. Giannattasio A, Albano F, Giacometi V, Guarino A. The changing pattern of adherence to antiretroviral therapy assessed at two time points, 12 months apart, in a cohort of HIV-infected children. Expert Opin Pharmacother. 2008; 10(17):2773–8. https://doi.org/10.1517/14656560903376178 PMID: 19929700